干扰素联合利巴韦林治疗丙肝肝硬化的临床研究

Clinical research on combined therapy of interferon and ribavirin for hepatitis C cirrhosis

目的探讨干扰素联合利巴韦林治疗丙肝肝硬化的临床疗效，为临床诊疗提供参考。方法选择我院在2010年6月-2014年5月期间收治的66例丙肝肝硬化代偿期患者作为研究对象，按照随机法分为观察组和对照组，对照组给予干扰素治疗，观察组在此基础上联合利巴韦林治疗，比较两组患者的肝功能、ChildPut出评分、肝脏纤维化指标、病毒学应答及治疗效果。结果治疗前两组ALT、AST、ALB、TBIL、HA、PC、LN等差异无统计学意义（P〉0．05）。治疗后观察组各项指标均优于对照组，差异有统计学意义（P〈0．05）；治疗48周后，观察组早期应答、完全应答及持续应答均显著优于对照组，差异有统计学意义（P〈0．05）。结论干扰素联合利巴韦林能明显促进丙肝肝硬化代偿患者的抗纤维化能力，同时使患者肝功能逐渐恢复。

Objective To explore the clinical efficiency of the combined therapy of interferon and ribavirin for the treatment of patients of hepatitis C cirrhosis. Methods Sixty-six patients with hepatitis C cirrhosis in compensatory period from June 2010 to May 2014 were recruited as research subjects and were randomly divided into the control group and the observation group. The control group was treated with interferon, and the observation group was treated with ribavirin in addition to interferon treatment. Child Pugh score, liver function and liver fibrosis indexes, virological response and therapeutic effect of both groups were compared and analyzed. Results There was no significant difference of ALT, AST, ALB and TBIL levels before treatment had no between the two groups （P 〉 0. 05）. After treatment, the above levels showed sta- tistical significance between two groups （P 〈 0.05）. Early response, complete response and sustained re- sponse of the observation group were better than those of the control group after 48 weeks of treatment （ P 〈 0. 05）. Conclusions The combined therapy of interferon and ribavirin can promote significantly anti-fibrosis ability in patients with hepatitis c cirrhosis and gradually improve the liver function at the same time.